US · Healthcare · Biotechnology
EPS came in at -0.08 against a street estimate of -0.06 — a miss of 33.3%.
with an average price target of $82.50.
| Fund | Stake |
|---|---|
| Invenomic Capital Management, LP | 1.39% |
| Vanguard Capital Management, LLC | 1.20% |
| Geode Capital Management, LLC | 1.01% |
| Citadel Advisors Llc | 0.63% |
| The Toronto-Dominion Bank | 0.40% |
| Vanguard Fiduciary Trust Co | 0.38% |
| HRT FINANCIAL LLC | 0.26% |
| UBS Group AG | 0.19% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lexaria Bioscience Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.